Skip to content

Study · Randomized controlled trial · n = 577 · 2020

13 results

Efficacy and safety of once-weekly semaglutide 1.0mg vs once-daily liraglutide 1.2mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10).

Capehorn MS, Catarig AM, Furberg JK, Janez A, Price HC, Tadayon S, Vergès B, Marre M

Diabetes & metabolism17 Sept 2019Cited by 308 (Europe PMC)

PMID31539622 (opens in a new tab)DOI10.1016/j.diabet.2019.101117 (opens in a new tab)PepBankPUB-31539622
Publisher pagePubMedAsk about this study
Jump to 13 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study13

13 results from studies that gave the peptide. 13 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes on oral antidiabetic drugs, semaglutide 1.0 mg lowered HbA1c more than liraglutide 1.2 mg at week 30.

    In plain wordsIn adults with type 2 diabetes, weekly semaglutide lowered HbA1c more than daily liraglutide at 30 weeks.

    Peptide
    Semaglutide
    Outcome
    DecreaseHbA1c change at week 30
    Study

    n = 577

    Comparator
    Liraglutide 1.2 mg once daily
    Analysis
    Primary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.0 mg once weekly · subcutaneous · 30 weeksAs given in this study (human).

    Measurements

    HbA1c decrease
    1.7%
    semaglutide 1.0 mg
    HbA1c decrease
    1%
    liraglutide 1.2 mg
    Estimated treatment difference
    −0.69%
    semaglutide vs liraglutide

    Source sentences

    Summary
    Mean HbA1c (baseline 8.2%) decreased by 1.7% with semaglutide and 1.0% with liraglutide (estimated treatment difference [ETD] -0.69%; 95% confidence interval [CI] -0.82 to -0.56, P<0.0001).
    1 context sentence
    Summary · context
    In this phase 3b, open-label trial, 577 adults with type 2 diabetes (HbA1c 7.0-11.0%) on 1-3 oral antidiabetic drugs were randomized 1:1 to subcutaneous once-weekly semaglutide 1.0mg or subcutaneous once-daily liraglutide 1.2mg.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes on oral antidiabetic drugs, liraglutide 1.2 mg lowered HbA1c by 1.0% at week 30, less than semaglutide.

    In plain wordsIn adults with type 2 diabetes, daily liraglutide lowered HbA1c, but by less than weekly semaglutide, at 30 weeks.

    Peptide
    Liraglutide
    Outcome
    DecreaseHbA1c change at week 30
    Study

    n: not reported in source

    Analysis
    Primary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.2 mg once daily · subcutaneous · 30 weeksAs given in this study (human).

    Measurements

    HbA1c decrease
    1%
    liraglutide 1.2 mg

    Source sentences

    Summary
    Mean HbA1c (baseline 8.2%) decreased by 1.7% with semaglutide and 1.0% with liraglutide (estimated treatment difference [ETD] -0.69%; 95% confidence interval [CI] -0.82 to -0.56, P<0.0001).
    1 context sentence
    Summary · context
    In this phase 3b, open-label trial, 577 adults with type 2 diabetes (HbA1c 7.0-11.0%) on 1-3 oral antidiabetic drugs were randomized 1:1 to subcutaneous once-weekly semaglutide 1.0mg or subcutaneous once-daily liraglutide 1.2mg.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes on oral antidiabetic drugs, semaglutide 1.0 mg reduced body weight more than liraglutide 1.2 mg at week 30.

    In plain wordsIn adults with type 2 diabetes, weekly semaglutide reduced body weight more than daily liraglutide at 30 weeks.

    Peptide
    Semaglutide
    Outcome
    DecreaseBody weight change at week 30
    Study

    n = 577

    Comparator
    Liraglutide 1.2 mg once daily
    Analysis
    Secondary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    1.0 mg once weekly · subcutaneous · 30 weeksAs given in this study (human).

    Measurements

    Body weight decrease
    5.8 kg
    semaglutide 1.0 mg
    Body weight decrease
    1.9 kg
    liraglutide 1.2 mg
    Estimated treatment difference
    −3.83 kg
    semaglutide vs liraglutide

    Source sentences

    Summary
    Mean body weight (baseline 96.9kg) decreased by 5.8kg with semaglutide and 1.9kg with liraglutide (ETD -3.83kg; 95% CI -4.57 to -3.09, P<0.0001).
    1 context sentence
    Summary · context
    In this phase 3b, open-label trial, 577 adults with type 2 diabetes (HbA1c 7.0-11.0%) on 1-3 oral antidiabetic drugs were randomized 1:1 to subcutaneous once-weekly semaglutide 1.0mg or subcutaneous once-daily liraglutide 1.2mg.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes on oral antidiabetic drugs, liraglutide 1.2 mg reduced body weight by 1.9 kg at week 30, less than semaglutide.

    In plain wordsIn adults with type 2 diabetes, daily liraglutide reduced body weight, but by less than weekly semaglutide, at 30 weeks.

    Peptide
    Liraglutide
    Outcome
    DecreaseBody weight change at week 30
    Study

    n: not reported in source

    Analysis
    Secondary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    1.2 mg once daily · subcutaneous · 30 weeksAs given in this study (human).

    Measurements

    Body weight decrease
    1.9 kg
    liraglutide 1.2 mg

    Source sentences

    Summary
    Mean body weight (baseline 96.9kg) decreased by 5.8kg with semaglutide and 1.9kg with liraglutide (ETD -3.83kg; 95% CI -4.57 to -3.09, P<0.0001).
    1 context sentence
    Summary · context
    In this phase 3b, open-label trial, 577 adults with type 2 diabetes (HbA1c 7.0-11.0%) on 1-3 oral antidiabetic drugs were randomized 1:1 to subcutaneous once-weekly semaglutide 1.0mg or subcutaneous once-daily liraglutide 1.2mg.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, more patients reached HbA1c below 7.0% with semaglutide than with liraglutide.

    In plain wordsIn adults with type 2 diabetes, more patients reached the HbA1c target below 7.0% with semaglutide than with liraglutide.

    Peptide
    Semaglutide
    Outcome
    IncreaseProportion with HbA1c below 7.0%
    Study

    n = 577

    Comparator
    Liraglutide 1.2 mg once daily
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.0 mg once weekly · subcutaneous · 30 weeksAs given in this study (human).

    Source sentences

    Summary
    The proportions of subjects achieving glycaemic targets of1c<7.0% without severe or blood glucose-confirmed symptomatic hypoglycaemia and no weight gain were greater with semaglutide vs liraglutide (all P<0.0001).
    1 context sentence
    Summary · context
    In this phase 3b, open-label trial, 577 adults with type 2 diabetes (HbA1c 7.0-11.0%) on 1-3 oral antidiabetic drugs were randomized 1:1 to subcutaneous once-weekly semaglutide 1.0mg or subcutaneous once-daily liraglutide 1.2mg.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, more patients reached the HbA1c target of 6.5% with semaglutide than with liraglutide.

    In plain wordsIn adults with type 2 diabetes, more patients reached the HbA1c target of 6.5% with semaglutide than with liraglutide.

    Peptide
    Semaglutide
    Outcome
    IncreaseProportion with HbA1c at or below 6.5%
    Study

    n = 577

    Comparator
    Liraglutide 1.2 mg once daily
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.0 mg once weekly · subcutaneous · 30 weeksAs given in this study (human).

    Source sentences

    Summary
    The proportions of subjects achieving glycaemic targets of1c<7.0% without severe or blood glucose-confirmed symptomatic hypoglycaemia and no weight gain were greater with semaglutide vs liraglutide (all P<0.0001).
    1 context sentence
    Summary · context
    In this phase 3b, open-label trial, 577 adults with type 2 diabetes (HbA1c 7.0-11.0%) on 1-3 oral antidiabetic drugs were randomized 1:1 to subcutaneous once-weekly semaglutide 1.0mg or subcutaneous once-daily liraglutide 1.2mg.
  7. 07HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, more patients achieved weight loss of 5% or more with semaglutide than with liraglutide.

    In plain wordsIn adults with type 2 diabetes, more patients lost at least 5% of body weight with semaglutide than with liraglutide.

    Peptide
    Semaglutide
    Outcome
    IncreaseProportion with weight loss of 5% or more
    Study

    n = 577

    Comparator
    Liraglutide 1.2 mg once daily
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    1.0 mg once weekly · subcutaneous · 30 weeksAs given in this study (human).

    Source sentences

    Summary
    The proportions of subjects achieving glycaemic targets of1c<7.0% without severe or blood glucose-confirmed symptomatic hypoglycaemia and no weight gain were greater with semaglutide vs liraglutide (all P<0.0001).
    1 context sentence
    Summary · context
    In this phase 3b, open-label trial, 577 adults with type 2 diabetes (HbA1c 7.0-11.0%) on 1-3 oral antidiabetic drugs were randomized 1:1 to subcutaneous once-weekly semaglutide 1.0mg or subcutaneous once-daily liraglutide 1.2mg.
  8. 08HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, more patients achieved weight loss of 10% or more with semaglutide than with liraglutide.

    In plain wordsIn adults with type 2 diabetes, more patients lost at least 10% of body weight with semaglutide than with liraglutide.

    Peptide
    Semaglutide
    Outcome
    IncreaseProportion with weight loss of 10% or more
    Study

    n = 577

    Comparator
    Liraglutide 1.2 mg once daily
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    1.0 mg once weekly · subcutaneous · 30 weeksAs given in this study (human).

    Source sentences

    Summary
    The proportions of subjects achieving glycaemic targets of1c<7.0% without severe or blood glucose-confirmed symptomatic hypoglycaemia and no weight gain were greater with semaglutide vs liraglutide (all P<0.0001).
    1 context sentence
    Summary · context
    In this phase 3b, open-label trial, 577 adults with type 2 diabetes (HbA1c 7.0-11.0%) on 1-3 oral antidiabetic drugs were randomized 1:1 to subcutaneous once-weekly semaglutide 1.0mg or subcutaneous once-daily liraglutide 1.2mg.
  9. 09HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, more patients met the composite endpoint of HbA1c below 7.0% without severe or symptomatic hypoglycaemia and no weight gain with semaglutide than with liraglutide.

    In plain wordsIn adults with type 2 diabetes, more patients met a combined blood sugar, hypoglycaemia and weight target with semaglutide than with liraglutide.

    Peptide
    Semaglutide
    Outcome
    IncreaseComposite endpoint: HbA1c below 7.0% without severe or symptomatic hypoglycaemia and no weight gain
    Study

    n = 577

    Comparator
    Liraglutide 1.2 mg once daily
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.0 mg once weekly · subcutaneous · 30 weeksAs given in this study (human).

    Source sentences

    Summary
    The proportions of subjects achieving glycaemic targets of1c<7.0% without severe or blood glucose-confirmed symptomatic hypoglycaemia and no weight gain were greater with semaglutide vs liraglutide (all P<0.0001).
    1 context sentence
    Summary · context
    In this phase 3b, open-label trial, 577 adults with type 2 diabetes (HbA1c 7.0-11.0%) on 1-3 oral antidiabetic drugs were randomized 1:1 to subcutaneous once-weekly semaglutide 1.0mg or subcutaneous once-daily liraglutide 1.2mg.
  10. 10HumanRandomized controlled trialSafety outcome

    In adults with type 2 diabetes, gastrointestinal disorders were more frequent with semaglutide than with liraglutide.

    In plain wordsIn adults with type 2 diabetes, stomach and gut problems were more frequent with semaglutide than with liraglutide.

    Peptide
    Semaglutide
    Outcome
    IncreaseGastrointestinal disorders
    Study

    n = 577

    Comparator
    Liraglutide 1.2 mg once daily
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    1.0 mg once weekly · subcutaneous · 30 weeksAs given in this study (human).

    Measurements

    Gastrointestinal disorders
    43.9%
    semaglutide
    Gastrointestinal disorders
    38.3%
    liraglutide

    Source sentences

    Summary
    more frequent gastrointestinal disorders (the most common adverse events [AEs]) and AEs leading to premature treatment discontinuation with semaglutide vs liraglutide (43.9% vs 38.3% and 11.4% vs 6.6%, respectively
    1 context sentence
    Summary · context
    In this phase 3b, open-label trial, 577 adults with type 2 diabetes (HbA1c 7.0-11.0%) on 1-3 oral antidiabetic drugs were randomized 1:1 to subcutaneous once-weekly semaglutide 1.0mg or subcutaneous once-daily liraglutide 1.2mg.
  11. 11HumanRandomized controlled trialSafety outcome

    In adults with type 2 diabetes, gastrointestinal disorders were less frequent with liraglutide than with semaglutide.

    In plain wordsIn adults with type 2 diabetes, stomach and gut problems were less frequent with liraglutide than with semaglutide.

    Peptide
    Liraglutide
    Outcome
    DecreaseGastrointestinal disorders
    Study

    n = 577

    Comparator
    Semaglutide 1.0 mg once weekly
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    1.2 mg once daily · subcutaneous · 30 weeksAs given in this study (human).

    Measurements

    Gastrointestinal disorders
    38.3%
    liraglutide

    Source sentences

    Summary
    more frequent gastrointestinal disorders (the most common adverse events [AEs]) and AEs leading to premature treatment discontinuation with semaglutide vs liraglutide (43.9% vs 38.3% and 11.4% vs 6.6%, respectively
    1 context sentence
    Summary · context
    In this phase 3b, open-label trial, 577 adults with type 2 diabetes (HbA1c 7.0-11.0%) on 1-3 oral antidiabetic drugs were randomized 1:1 to subcutaneous once-weekly semaglutide 1.0mg or subcutaneous once-daily liraglutide 1.2mg.
  12. 12HumanRandomized controlled trialSafety outcome

    In adults with type 2 diabetes, adverse events leading to premature treatment discontinuation were more frequent with semaglutide than with liraglutide.

    In plain wordsIn adults with type 2 diabetes, more people stopped treatment early because of side effects with semaglutide than with liraglutide.

    Peptide
    Semaglutide
    Outcome
    IncreaseAdverse events leading to premature discontinuation
    Study

    n = 577

    Comparator
    Liraglutide 1.2 mg once daily
    Outcome group
    Adverse events · Whole body
    Studied dose
    1.0 mg once weekly · subcutaneous · 30 weeksAs given in this study (human).

    Measurements

    Discontinuation due to adverse events
    11.4%
    semaglutide
    Discontinuation due to adverse events
    6.6%
    liraglutide

    Source sentences

    Summary
    more frequent gastrointestinal disorders (the most common adverse events [AEs]) and AEs leading to premature treatment discontinuation with semaglutide vs liraglutide (43.9% vs 38.3% and 11.4% vs 6.6%, respectively
    1 context sentence
    Summary · context
    In this phase 3b, open-label trial, 577 adults with type 2 diabetes (HbA1c 7.0-11.0%) on 1-3 oral antidiabetic drugs were randomized 1:1 to subcutaneous once-weekly semaglutide 1.0mg or subcutaneous once-daily liraglutide 1.2mg.
  13. 13HumanRandomized controlled trialSafety outcome

    In adults with type 2 diabetes, adverse events leading to premature treatment discontinuation were less frequent with liraglutide than with semaglutide.

    In plain wordsIn adults with type 2 diabetes, fewer people stopped treatment early because of side effects with liraglutide than with semaglutide.

    Peptide
    Liraglutide
    Outcome
    DecreaseAdverse events leading to premature discontinuation
    Study

    n = 577

    Comparator
    Semaglutide 1.0 mg once weekly
    Outcome group
    Adverse events · Whole body
    Studied dose
    1.2 mg once daily · subcutaneous · 30 weeksAs given in this study (human).

    Measurements

    Discontinuation due to adverse events
    6.6%
    liraglutide

    Source sentences

    Summary
    more frequent gastrointestinal disorders (the most common adverse events [AEs]) and AEs leading to premature treatment discontinuation with semaglutide vs liraglutide (43.9% vs 38.3% and 11.4% vs 6.6%, respectively
    1 context sentence
    Summary · context
    In this phase 3b, open-label trial, 577 adults with type 2 diabetes (HbA1c 7.0-11.0%) on 1-3 oral antidiabetic drugs were randomized 1:1 to subcutaneous once-weekly semaglutide 1.0mg or subcutaneous once-daily liraglutide 1.2mg.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials3

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

3 trials · 2 ongoing · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

RecruitingPhase 2/3NCT07284511

A Clinical Trial Using Tirzepatide to Help Adults With Type 1 Diabetes Automatically Control Their Blood Sugar

McGill University Health Centre/Research Institute of the McGill University Health Centren = 10519 May 2026 to est. Jan 2029

Type 1 Diabetes · Type 1 Diabetes Mellitus · T1D · T1DM · T1DM - Type 1 Diabetes Mellitus

Trial pageClinicalTrials.govUpdated 27 May 2026
RecruitingPhase 3NCT06894784

A Clinical Trial to Evaluate The Effects of Semaglutide and Empagliflozin Combined to Automated Insulin Delivery on Diabetes Control in Adults Living With Type 1 Diabetes

McGill University Health Centre/Research Institute of the McGill University Health Centren = 36est. Apr 2025 to est. Jan 2027

Diabetes Type 1

Trial pageClinicalTrials.govUpdated 30 Mar 2025
CompletedPhase 3Results postedNCT03191396

Research Study Comparing a New Medicine Semaglutide to Liraglutide in People With Type 2 Diabetes

Novo Nordisk A/Sn = 57727 Jun 2017 to 13 Aug 2018

Diabetes · Diabetes Mellitus, Type 2

Trial pageClinicalTrials.govUpdated 15 Oct 2019

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:06 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.